WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Klee, S ^a,b   Lehmann, M ^a,b   Wagner, D E ^a,b   Baarsma, H A ^a,b   Konigshoff, M ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCN PROTEIN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; WISP1 PROTEIN, HUMAN;

BIOLOGICAL MODEL; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENETICS; HUMAN; LUNG; LUNG FIBROSIS; METABOLISM; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

CCN INTERCELLULAR SIGNALING PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERLEUKIN-6; LUNG; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958078660     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20547     Document Type: Article

References (47)

1. Selman, M. et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134, 136-151 (2001).
2. King, T. E. Jr., Pardo, A., Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961 (2011).
3. King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370, 2083-2092 (2014).
4. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370, 2071-2082 (2014).
5. Fernandez, I. E., Eickelberg, O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380, 680-688 (2012).
6. Wolters, P. J., Collard, H. R., Jones, K. D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 9, 157-179 (2014).
7. Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183, 788-824 (2011).
8. Berschneider, B., Konigshoff, M. WNT1 inducible signaling pathway protein 1 (WISP1): a novel mediator linking development and disease. Int J Biochem Cell Biol 43, 306-309 (2011).
9. Holbourn, K. P., Acharya, K. R., Perbal, B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33, 461-473 (2008).
10. Yang, M. et al. A role for WNT1-inducible signaling protein-1 in airway remodeling in a rat asthma model. Int Immunopharmacol 17, 350-357 (2013).
11. Sharma, S. et al. A role for Wnt signaling genes in the pathogenesis of impaired lung function in asthma. Am J Respir Crit Care Med 181, 328-336 (2010).
12. Yang, M., Du, Y., Xu, Z., Jiang, Y. Functional Effects of WNT1-Inducible Signaling Pathway Protein-1 on Bronchial Smooth Muscle Cell Migration and Proliferation in OVA-Induced Airway Remodeling. Inflammation (2015).
13. Konigshoff, M. et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119, 772-787 (2009).
14. Scotton, C. J. et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 119, 2550-2563 (2009).
15. Berschneider, B. et al. miR-92a regulates TGF-beta1-induced WISP1 expression in pulmonary fibrosis. Int J Biochem Cell Biol 53, 432-441 (2014).
16. Piguet, P. F., Vesin, C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 7, 515-518 (1994).
17. Bonniaud, P. et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171, 889-898 (2005).
18. Aumiller, V., Balsara, N., Wilhelm, J., Gunther, A., Konigshoff, M. WNT/beta-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol 49, 96-104 (2013).
19. Xu, L., Corcoran, R. B., Welsh, J. W., Pennica, D., Levine, A. J. WISP-1 is a Wnt-1-and beta-catenin-responsive oncogene. Genes Dev 14, 585-595 (2000).
20. Whyte, M. et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factoralpha gene polymorphisms. Am J Respir Crit Care Med 162, 755-758 (2000).
21. Piguet, P. F., Collart, M. A., Grau, G. E., Kapanci, Y., Vassalli, P. Tumor necrosis factor/cachectin plays a key role in bleomycininduced pneumopathy and fibrosis. J Exp Med 170, 655-663 (1989).
22. Eickelberg, O. et al. Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem 274, 12933-12938 (1999).
23. Jia, Y. et al. Regulation of lung fibroblast activation by annexin A1. J Cell Physiol 228, 476-484 (2013).
24. Park, J. I. et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22, 4314-4332 (2003).
25. Takizawa, H. et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 107, 175-181 (1997).
26. Le, T. T. et al. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol 193, 3755-3768 (2014).
27. Fries, K. M., Felch, M. E., Phipps, R. P. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am J Respir Cell Mol Biol 11, 552-560 (1994).
28. Shahar, I. et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin Immunol Immunopathol 79, 244-251 (1996).
29. Nicholson, A. G. et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166, 173-177 (2002).
30. Pennica, D. et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 95, 14717-14722 (1998).
31. Konigshoff, M. et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 3, e2142 (2008).
32. Henderson, W. R. Jr. et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 107, 14309-14314 (2010).
33. Ulsamer, A. et al. Axin pathway activity regulates in vivo pY654-beta-catenin accumulation and pulmonary fibrosis. J Biol Chem 287, 5164-5172 (2012).
34. O'Donoghue, R. J. et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med 4, 939-951 (2012).
35. Venkatachalam, K. et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 284, 14414-14427 (2009).
36. Nagai, Y. et al. Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res 31, 991-997 (2011).
37. Liu, H. et al. CCN4 regulates vascular smooth muscle cell migration and proliferation. Mol Cells 36, 112-118 (2013).
38. Chiang, K. C. et al. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci Rep 5, 8686 (2015).
39. Gyotoku, E. et al. The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice. Arch Dermatol Res 293, 508-514 (2001).
40. You, J. J., Yang, C. H., Yang, C. M., Chen, M. S. Cyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin alphanubeta3, FAK, PI3K/Akt, and NF-kappaB pathways in retinal vascular endothelial cells. Cell Signal 26, 133-140 (2014).
41. Wu, S. H., Lu, C., Dong, L., Chen, Z. Q. Signal transduction involved in CTGF-induced production of chemokines in mesangial cells. Growth Factors 26, 192-200 (2008).
42. Chen, P. C., Lin, T. H., Cheng, H. C., Tang, C. H. CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis 33, 937-945 (2012).
43. Hou, C. H., Tang, C. H., Hsu, C. J., Hou, S. M., Liu, J. F. CCN4 induces IL-6 production through alphavbeta5 receptor, PI3K, Akt, and NF-kappaB singling pathway in human synovial fibroblasts. Arthritis Res Ther 15, R19 (2013).
44. Leask, A., Abraham, D. J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119, 4803-4810 (2006).
45. Sheppard, D. The role of integrins in pulmonary fibrosis. Eur Respir Rev 17, 157-162 (2008).
46. Zhou, Y., Hagood, J. S., Lu, B., Merryman, W. D., Murphy-Ullrich, J. E. Thy-1-integrin alphav beta5 interactions inhibit lung fibroblast contraction-induced latent transforming growth factor-beta1 activation and myofibroblast differentiation. J Biol Chem 285, 22382-22393 (2010).
47. Staab-Weijnitz, C. A. et al. FK506-binding Protein 10 is a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2015).